Page last updated: 2024-12-06

lividomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID72394
CHEMBL ID389029
CHEBI ID71961
SCHEMBL ID195432
MeSH IDM0263411

Synonyms (46)

Synonym
lividomycin a ,
(2r,3s,4s,5s,6r)-2-((2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-((2r,3s,4r,5s)-5-((1r,2r,3s,5r,6s)-3,5-diamino-2-((2s,3r,5s,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-4-hydroxy-2-(hydroxymethyl)-tetrahydrof
LIV ,
(1r,2r,3s,4r,6s)-4,6-diamino-3-hydroxy-2-{[alpha-d-mannopyranosyl-(1->4)-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-beta-d-ribofuranosyl]oxy}cyclohexyl 2-amino-2,3-dideoxy-alpha-d-ribo-hexopyranoside
livodymycin
lvm
36441-41-5
lividomycin
(2r,3s,4s,5s,6r)-2-[(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,5s,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-
DB04728
antibiotic sf 767 a
mannosyldeoxyparomomycin
lividomycine [inn-french]
lividomicina [inn-spanish]
d-streptamine, o-2-amino-2,3-dideoxy-alpha-d-ribo-hexopyranosyl-(1-4)-o- (o-alpha-d-mannopyranosyl-(1-4)-o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-beta-d-ribofuranosyl-(1-5))-2-deoxy-
o-2-amino-2,3-dideoxy-alpha-d-ribo-hexopyranosyl-(1->4)-o-(o-alpha-d-mannopyranosyl-(1->4)-o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-beta-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine
quintomycin b
antibiotic 503-2
lividomycinum [inn-latin]
sf 767 a
brn 6763509
lividomycin [inn:dcf]
o-2-amino-2,3-dideoxy-alpha-d-ribo-hexopyranosyl-(1-4)-o-(o-alpha-d-mannopyranosyl-(1-4)-o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-beta-d-ribofuranosyl-(1-5))-2-deoxy-d-streptamine
chebi:71961 ,
CHEMBL389029
(2r,3s,4s,5s,6r)-2-[(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,5s,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-4-hydroxyoxa
C17707
11111-23-2
a606aj494w ,
lividomycine
unii-a606aj494w
lividomycinum
lividomicina
lividomycin a sulfate salt
o-2-amino-2,3-dideoxy-.alpha.-d-ribo-hexopyranosyl-(1->4)-o-(o-.alpha.-d-mannopyranosyl-(1->4)-o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine
lividomycin [inn]
SCHEMBL195432
DTXSID8023218
(2r,3s,4s,5s,6r)-2-((2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-((2r,3s,4r,5s)-5-((1r,2r,3s,5r,6s)-3,5-diamino-2-((2s,3r
hyl)-tetrahydrofuran-3-yloxy)-4-hydroxy-tetrahydro-2h-pyran-3-yloxy)-6-(hydroxymethyl)-tetrahydro-2h-pyran-3,4,5-triol
,5s,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-4-hydroxy-2-(hydroxymet
Q6658885
bdbm50534265
d-streptamine, o-alpha-d-mannopyranosyl-(1-->4)-o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-->3)-o-beta-d-ribofuranosyl-(1-->5)-o-[2-amino-2,3-dideoxy-alpha-d-ribo-hexopyranosyl-(1-->4)]-2-deoxy-
(2r,3s,4s,5s,6r)-2-(((2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-(((2r,3s,4r,5s)-5-(((1r,2r,3s,5r,6s)-3,5-diamino-2-(((2s,3r,5s,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahy
AKOS040752615
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
lividomycinsAny member of a family of aminoglycosidic antibiotics produced by the bacterium Streptomyces lividus. Note that one member of this class, lividomycin A, is also known as lividomycin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosyl-DNA phosphodiesterase 1Homo sapiens (human)IC50 (µMol)30,000.00000.01203.32138.4300AID1631084
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
single strand break repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
DNA repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
double-strand break repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
double-stranded DNA bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
single-stranded DNA bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
exonuclease activityTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
protein bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
3'-tyrosyl-DNA phosphodiesterase activityTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleoplasmTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
cytoplasmTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
plasma membraneTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
intracellular membrane-bounded organelleTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
nucleusTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID278804Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD [aph(3')-2] in the presence of arabinose2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID199517Compound was tested for the inhibition of Rev-RBE RNA complex formation1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.
AID65062Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID278806Antimicrobial activity against Stenotrophomonas maltophilia K279a (aph FS) mutant2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID278801Antimicrobial activity against recombinant Escherichia coli DH5alpha expressing pBAD2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID65059Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K121987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1631084Inhibition of TDP1 (unknown origin) using 14-mer duplex oligonucleotide [32P]-D14Y as substrate incubated for 20 mins by PAGE analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
AID212902Inhibition of human telomerase after assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID278802Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD in the presence of arabinose2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID375076Binding affinity to A-site RNA2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID65067Percent killing of the total Escherichia coli K12 (ATCC 25868)cells at the C50 concentration was determined.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID212744Inhibition of telomerase before assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID278805Antimicrobial activity against Stenotrophomonas maltophilia K279a mutant2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID65071Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID212741Inhibition of purified telomerase of Euplotes aediculatus at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID278803Antimicrobial activity against recombinant Escherichia coli DHalpha expressing pBAD [aph(3')-2]2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID212903Inhibition of human telomerase before assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID212743Inhibition of telomerase after assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.35)18.7374
1990's4 (17.39)18.2507
2000's13 (56.52)29.6817
2010's3 (13.04)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.53 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]